Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG’s Regorafenib Recommended For Approval In European Union For Treatment Of Metastatic Colorectal Cancer


Friday, 28 Jun 2013 09:56am EDT 

Bayer AG announced that the Company’s oncology compound regorafenib has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. The decision of the European Commission on the approval is expected in the third quarter of 2013. 

Company Quote

100.8
-2.35 -2.28%
11:35am EDT